*Author for correspondence Asian Journal of Pharmaceutical Research and Health Care, Vol 13(1), 17-29, 2021 ISSN (Online) : 2250-1460 DOI: 10.18311/ajprhc/2021/26066 Abstract Doxorubicin (DXR) is widely indicated as anticancer drug, but serious cardiotoxicity limits its clinical application. Recently, Pravastatin (PS) is one of the statins that appear to possess a potential role in cancer therapy despite its hepatotoxicity. Interestingly, drug delivery systems are designed for targeted and controlled delivery of one or more drugs loaded in nanoparticles, holding an enormous potential in therapeutics. Therefore, the aim of the current study was to assess the tolerability of a novel nanoemulsion formulation holding DXR and pravastatin (DXR+PS/LNE) in Swiss albino mice bearing Ehrlich Ascites Carcinoma (EAC). The efficacy and tolerability of nanoemulsion formulation was assessed by monitoring body weight changes, biochemical and histopathological profiles of cardiac and hepatic tissues. The formulated DXR+PS/ LNE has mean droplet diameter of 139.90±3.85 nm. The present findings indicated that DXR+PS/LNE caused a significant decrease in body weight change and a 217.35 % increase in the mean survival time compared to EAC-challenged mice. In addition, no significant changes in biochemical parameters were detected compared to corresponding controls. The current preclinical results suggest that the nanoemulsion formulation of doxorubicin with pravastatin could be a promising novel cancer therapy, in terms of tolerability. Doxorubicin Supplemented with Pravastatin in Lipid Nanoemulsion Induces Antineoplastic Activity with Limited Hepatotoxicity and Cardiotoxicity in Tumor-Bearing Mice Mayson H. Alkhatib 1,2* , Huda M. Alkreathy 3 , Mashael I. Al Omar 1 , Khadijah S. Balamash 1 , Faiza Abdu 4 and Ahmad Esmat 3, 5 1 Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia; mhalkhatib@kau.edu.sa 2 Regenerative Medicine Unit King Fahd Center for Medical Research, King Abdulaziz University, Jeddah, Saudi Arabia 3 Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia 4 Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia 5 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo - 11566, Egypt 1. Introduction Cancer is a potentially fatal ailment, caused by uncontrolled proliferation and metastases of abnormal cells. Chemotherapy can be defned as the use of anticancer drugs either single or in combination with Keywords: Cardiac Tissue, Ehrlich Ascites Carcinoma, Hepatic Tissue, Mean Survival Time, Statins, Transmission Electron Microscope other drugs to restrict the cancer progression. Various frontline chemotherapeutic agents, employed in oncology, are having many challenges like rapid drug clearance, low water solubility, low tolerability and non-specifc tumor targeting; thereby damaging healthy cells during the treatment 1 .